Glucagon-like peptide-1 : New target for treating non-alcoholic fatty liver disease?

非酒精性脂肪性肝病(NAFLD)患者存在胰升糖素样肽1(GLP-1)信号受损.天然GLP-1或GLP-1类药物可通过GLP-1受体对肝细胞发挥直接作用,包括改善胰岛素抵抗、抑制氧化应激、调控脂代谢相关基因表达等.临床研究显示GLP-1类药物能够改善NAFLD患者的代谢指标和肝脏病变.Recent studies have demonstrated an association of glucagon-like peptide-1 (GLP-1) signaling defect with non-alcoholic fatty liver disease (NAFLD).Native GLP-1 and GLP-1-based agents may directly act on hepatocytes through activation of GLP-1 receptors in hepatocytes,resulting in the regulation of gene expression associated with insulin resistance and lipid metabolism,and the suppression of oxidative stress in liver cells.Moreover,GLP-1-based agents have been reported to be effective in improving hepatic endpoints in patients with NAFLD.国家973计划资助项目; 国家自然科学基金资助项目; 高等教育博士学科点新教师基金资助项目中文核心期刊要目总览(PKU)中国科技核心期刊(ISTIC)中国科学引文数据库(CSCD)5386-3893